Skip to main content

Find Clinical Trials

Home
Conditions
Sintilimab

Clinical trial condition

Sintilimab

Explore clinical trials studying Sintilimab. Study availability and eligibility vary by location and protocol.

14 public trials 8 recruiting studies

Refine in advanced search Browse all conditions

Sintilimab trial results

Recruiting

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

NCT07506109

Conditions: BRAF V600E, Brain Diseases, Central Nervous System Diseases, +25 more
Locations: Peking union medical college hospital Beijing, Beijing Municipality, China

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China

West China Hospital Sichuan University Chengdu, Sichuan, China

Tianjin Medical University Cancer Institute and Hospital Tianjin, Tianjin Municipality, China

View Trial Details

Recruiting

The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients

NCT07138755

Conditions: Adaptive Radiotherapy, Bronchial Neoplasms, Carcinoma, Bronchogenic, +10 more
Locations: Xiangya 3rd Hospital, Central South University Changsha, Hunan, China

View Trial Details

Recruiting

Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma

NCT07416890

Conditions: Central Nervous System Lymphoma, Pirtobrutinib, Sintilimab
Locations: Zhejiang Cancer Hospital Hangzhou, Zhejiang, China

View Trial Details

Recruiting

Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma

NCT07324824

Conditions: Adenocarcinoma, Bevacizimab, Carcinoma, +12 more
Locations: Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China

View Trial Details

Recruiting

Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC

NCT06714708

Conditions: Low Dose Radiotherapy, NSCLC, Neoadjuvant Immunotherapy, +1 more
Locations: Anhui Provincial Cancer Hospital Hefei, Anhui, China

View Trial Details

Recruiting

bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma

NCT06070636

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +12 more
Locations: Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China

View Trial Details

Recruiting

Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma

NCT06413342

Conditions: Chemoradiotherapy, Digestive System Diseases, Digestive System Neoplasms, +11 more
Locations: Zhejiang Cancer Hospital Hangzhou, Zhejiang, China

View Trial Details

Recruiting

Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

NCT05707819

Conditions: Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Carcinoma, +12 more
Locations: Guangxi Medical University Cancer Hospital Nanning, Guangxi, China

View Trial Details

Not Yet Recruiting

Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer

NCT06459921

Conditions: Locally Advanced Gastric Cancer, Neoadjuvant Chemotherapy, Sintilimab
Locations: Not specified

View Trial Details

Completed

Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)

NCT04271813

Conditions: Anlotinib, Chemo-free Therapy, Colonic Diseases, +14 more
Locations: Department of Medical Oncology, Shanghai Changzheng Hospital Shanghai, China

View Trial Details